Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial Meeting Abstract
| Authors: | George, D. J.; Hessel, C.; Halabi, S.; Sanford, B. L.; Michaelson, M. D.; Hahn, O. M.; Walsh, M. K.; Olencki, T.; Picus, J.; Small, E. J.; Dakhil, S. R.; Feldman, D. R.; Mangeshkar, M.; Scheffold, C.; Morris, M. J.; Choueiri, T. K. |
| Abstract Title: | Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500575 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.582 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 582 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
